Akari Therapeutics
(AKTX)
undefined
undefined%
At close: undefined
0.97
-2.70%
After-hours Dec 13, 2024, 03:59 PM EST
Company Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.
Akari Therapeutics, Plc is based in London, the United Kingdom.
Akari Therapeutics
| Country | GB |
| IPO Date | Jan 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. Samir Rashmikant Patel M.D. |
Contact Details
Address: 75/76 Wimpole Street London, GB | |
| Website | https://www.akaritx.com |
Stock Details
| Ticker Symbol | AKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001541157 |
| CUSIP Number | 00972G108 |
| ISIN Number | US00972G2075 |
| Employer ID | 98-1034922 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Samir Rashmikant Patel M.D. | Interim President, Chief Executive Officer & Director |
| Wendy F. DiCicco CPA | Interim Chief Financial Officer |
| Dr. Miles Nunn | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 8-K | Current Report |
| Dec 06, 2024 | SC 13D/A | [Amend] Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Nov 22, 2024 | 3 | Filing |
| Nov 22, 2024 | 3 | Filing |
| Nov 22, 2024 | 3 | Filing |
| Nov 19, 2024 | 10-Q | Quarterly Report |
| Nov 18, 2024 | 4 | Filing |
| Nov 15, 2024 | NT 10-Q | Filing |